Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercus ilex and Quercus robur allergenic extracts – in vivo allergenic potency (HEP)
2020-005388-30Phase 2Active
- Sponsor
- Inmunotek
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Quercus ilex pollen allergen extract and quercus robur pollen extract in seasonal allergic rhinitis (SAR), allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and 1 more (2 arms), sponsored by Inmunotek. Primary endpoint: Skin wheal area for each allergen extract concentration and controls. Started Jun 2022; status: active.
02
Drugs
Quercus ilex pollen allergen extractquercus robur pollen extract
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2020-005388-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005388-30.